Dorval Allison

SEC Form 4 insider trading activity

Dorval Allison has filed 1 SEC Form 4 filing (2 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Jun 15, 2026.

On the most recent filing, Dorval Allison is listed as Director at PUMA BIOTECHNOLOGY, INC. Inside the rolling window, Dorval Allison reported no open-market purchases and 1 open-market sale totaling $84K in PBYI.

Companies traded

Other insiders at PBYI

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$84K

reported sales (SEC code S)

Companies

1

in the rolling window

Source
PBYI
Dorval Allison
Sale$84KJun 15SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Dorval Allison made?

Dorval Allison has filed 1 SEC Form 4 filing (2 transaction rows) across 1 company since 2026.

Which companies does Dorval Allison trade?

Dorval Allison has filed SEC Form 4 disclosures for 1 company, including PBYI.

When was Dorval Allison's most recent SEC Form 4 filing?

Dorval Allison's most recent SEC Form 4 filing on Tracefour is dated Jun 15, 2026.

What is Dorval Allison's total buy and sell value in the current window?

Inside the rolling retention window, Dorval Allison bought $0 and sold $84K based on SEC Form 4 filings.

What was Dorval Allison's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 11,610 PBYI shares on 2026-06-12, worth $84K, per SEC Form 4 filings.